Imfinzi and Lynparza in Advanced Endometrial Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- June 7, 2023
- Reading time: 1 minute
On May 26, 2023, AstraZeneca announced significant results from the Phase 3 DUO-E clinical trial evaluating patients with advanced or recurrent endometrial cancer.
Study Design: The DUO-E trial evaluated patients receiving Imfinzi (durvalumab) in combination with platinum-based chemotherapy or chemotherapy alone as first-line treatment. Following the initial phase, patients received maintenance therapy with either Imfinzi plus Lynparza (olaparib) or Imfinzi monotherapy.
Clinical Outcomes: The trial reported that both maintenance regimens significantly prolonged progression-free survival (PFS) compared with standard chemotherapy (literature data; for reference only). The combination of Imfinzi and Lynparza was particularly noted for providing substantial clinical benefit. While overall survival (OS) data is still maturing, a positive trend toward improved OS was observed in both treatment arms.
Safety Profile: The safety and tolerability profile was consistent with the known side effects of each individual agent observed in previous clinical evaluations. Detailed findings from the trial are expected to be presented at an upcoming medical congress.
Source: AstraZeneca Press Release.
- Clinical Trial Medications
- Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Trastuzumab deruxtecan in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4